• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

烟酰胺配位的铂(IV)-钌(II)嵌合配合物在体内具有协同抑制肿瘤转移和生长的作用,同时潜在降低毒性。

Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity in vivo.

机构信息

The First Affiliated Hospital, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, School of Medicine, Zhejiang University, Hangzhou, 310003, P. R. China.

Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, P. R. China.

出版信息

Chem Commun (Camb). 2020 Mar 10;56(20):3069-3072. doi: 10.1039/c9cc09016a.

DOI:10.1039/c9cc09016a
PMID:32049075
Abstract

Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes (PtRu 1-4) have been synthesized and evaluated for their antitumor performance. Using the optimal complex, PtRu-1, we show that this water-soluble chimeric prodrug not only potently inhibits the metastasis and proliferation of tumor cells but also has an unexpectedly higher safety margin in animals compared with the traditionally-used, clinically approved drug cisplatin.

摘要

已合成烟酸连接的铂(IV)-钌(II)嵌合配合物(PtRu1-4),并对其抗肿瘤性能进行了评估。使用最佳配合物 PtRu-1,我们表明这种水溶性嵌合前药不仅能强烈抑制肿瘤细胞的转移和增殖,而且与传统的临床批准药物顺铂相比,在动物体内具有出人意料的更高安全性。

相似文献

1
Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity in vivo.烟酰胺配位的铂(IV)-钌(II)嵌合配合物在体内具有协同抑制肿瘤转移和生长的作用,同时潜在降低毒性。
Chem Commun (Camb). 2020 Mar 10;56(20):3069-3072. doi: 10.1039/c9cc09016a.
2
A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.一种癌细胞选择性且低毒的双功能异双核铂(IV)-钌(II)抗癌前药。
Inorg Chem. 2018 Mar 5;57(5):2917-2924. doi: 10.1021/acs.inorgchem.8b00053. Epub 2018 Feb 13.
3
Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.铂(IV)配合物与查耳酮类似物缀合物作为双重靶向抗癌剂:体外和体内研究。
Bioorg Chem. 2020 Dec;105:104430. doi: 10.1016/j.bioorg.2020.104430. Epub 2020 Oct 27.
4
New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.一类新型的带有水溶性CAP配体的半三明治型钌(II)芳烃配合物作为体外抗癌剂
Inorg Chem. 2017 May 15;56(10):5514-5518. doi: 10.1021/acs.inorgchem.7b00915. Epub 2017 Apr 26.
5
[Ru(phen)podppz] significantly inhibits glioblastoma growth in vitro and vivo with fewer side-effects than cisplatin.[Ru(phen)podppz] 比顺铂具有更少的副作用,能显著抑制体外和体内脑胶质瘤的生长。
Dalton Trans. 2020 Jul 7;49(26):8864-8871. doi: 10.1039/d0dt01877e.
6
A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies.一种可穿透核的基于 Ru(ii)的光激活化疗药物对一系列癌细胞的作用:体外和体内研究。
Dalton Trans. 2019 May 15;48(19):6492-6500. doi: 10.1039/c9dt00441f.
7
Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex.一种缺电子有机钌(II)配合物的临床前抗癌活性。
ChemMedChem. 2020 Jun 4;15(11):982-987. doi: 10.1002/cmdc.202000096. Epub 2020 Apr 27.
8
Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.新型含圣草酚配体的 Pt(IV) 配合物通过抑制 Rap1b 介导的食管鳞癌细胞干性逆转顺铂诱导的耐药性在食管鳞癌治疗中。
Bioorg Chem. 2024 Jun;147:107384. doi: 10.1016/j.bioorg.2024.107384. Epub 2024 Apr 16.
9
A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).一种通过上调p27(KIP1)来阻断进入S期的细胞周期抑制性钌(II)-铂(II)双(三联吡啶)抗癌复合物。
Chemistry. 2015 Jun 15;21(25):9185-97. doi: 10.1002/chem.201500561. Epub 2015 May 7.
10
New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules.新型取代三联吡啶配体的铂(II)和钯(II)配合物的合成与表征、细胞毒性及与生物分子的反应性。
Biometals. 2019 Feb;32(1):33-47. doi: 10.1007/s10534-018-0155-x. Epub 2018 Oct 26.

引用本文的文献

1
Recent Advances on the Role of B Vitamins in Cancer Prevention and Progression.B族维生素在癌症预防和进展中的作用的最新进展
Int J Mol Sci. 2025 Feb 25;26(5):1967. doi: 10.3390/ijms26051967.
2
Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth-An Investigation of the Activation Mechanism and Their Nanoformulation.吉西他滨和卡培他滨功能化的奥沙利铂(IV)前药诱导结直肠癌细胞生长阻滞——激活机制及其纳米制剂的研究
Pharmaceutics. 2024 Feb 16;16(2):278. doi: 10.3390/pharmaceutics16020278.
3
Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models.
具有显著抗癌活性的铂(IV)-金(I)制剂:二维和三维三阴性乳腺癌模型中的精选研究
Chemistry. 2023 Oct 23;29(59):e202302045. doi: 10.1002/chem.202302045. Epub 2023 Sep 5.
4
Exploration of Antiproliferative Activity and Apoptosis Induction of New Nickel(II) Complexes Encompassing Carbazole Ligands.含咔唑配体的新型镍(II)配合物的抗增殖活性及诱导凋亡作用的研究
ACS Omega. 2023 Mar 22;8(13):12584-12591. doi: 10.1021/acsomega.3c01252. eCollection 2023 Apr 4.
5
Promising heterometallic compounds as anticancer agents: Recent studies in vivo.具有前景的杂金属化合物作为抗癌剂:体内的最新研究。
Curr Opin Chem Biol. 2023 Feb;72:102250. doi: 10.1016/j.cbpa.2022.102250. Epub 2022 Dec 23.